Objective—To evaluate the use of piroxicam for the
treatment of oral squamous cell carcinoma in dogs.
Design—Prospective case series.
Animals—17 dogs with measurable oral squamous
Procedure—Dogs were treated with piroxicam at a
dosage of 0.3 mg/kg (0.14 mg/lb) of body weight, PO,
every 24 hours until progressive disease or unacceptable
signs of toxicosis developed or the dog died.
Results—One dog had a complete remission (maxillary
tumor), and 2 dogs had partial remissions (lingual
tumor and tonsillar tumor). An additional 5 dogs had
stable disease, including 1 with a maxillary tumor, 2
with mandibular tumors, and 2 with tonsillar tumors.
Variables associated with tumor response were not
identified. Median and mean times to failure for the 3
dogs that had a remission were 180 and 223 days,
respectively. Median and mean times to failure for the
5 dogs with stable disease were 102 and 223 days,
respectively. Time to failure was positively associated
with tumor response and negatively associated with
tumor size. One dog had mild adverse gastrointestinal
tract effects that resolved with the addition of misoprostol
to the treatment regimen.
Conclusions and Clinical Relevance—Results suggest
that piroxicam may be useful in the treatment of
dogs with oral squamous cell carcinoma; response
rate was similar to that reported for other cytotoxic
treatments. Larger-scale studies are warranted to
determine what role piroxicam may have, alone or in
combination with other treatments, for the treatment
of dogs with oral squamous cell carcinoma. (J Am Vet
Med Assoc 2001;218:1783–1786)
Objective—To determine the antitumor effects and toxicoses of metronomic oral administration of a low dose of chlorambucil in dogs with transitional cell carcinoma (TCC).
Design—Prospective clinical trial.
Animals—31 client-owned dogs with TCC for which prior treatments had failed or owners had declined other treatments.
Procedures—Chlorambucil (4 mg/m2, PO, q 24 h) was administered to dogs. Before and at scheduled times during treatment, evaluations of dogs included physical examination, CBC, serum biochemical analyses, urinalysis, thoracic and abdominal imaging including cystosonography for measurement of TCCs, and grading of toxicoses.
Results—29 of 31 dogs had failed prior TCC treatment. Of the 30 dogs with available data, 1 (3%) had partial remission (≥ 50% reduction in tumor volume), 20 (67%) had stable disease (< 50% change in tumor volume), and 9 (30%) had progressive disease (≥ 50% increase in tumor volume or development of additional tumors); 1 dog was lost to follow-up. The median progression-free interval (time from the start of chlorambucil treatment to the day progressive disease was detected) for the dogs was 119 days (range, 7 to 728 days). The median survival time of dogs from the time of the start of chlorambucil treatment was 221 days (range, 7 to 747 days). Few toxicoses were detected; chlorambucil administration was discontinued because of toxicoses in only 1 dog.
Conclusions and Clinical Relevance—Metronomic administration of chlorambucil was well tolerated, and 70% of dogs had partial remission or stable disease. Metronomic administration of chlorambucil may be a treatment option for dogs with TCC.